Centene/$CNC
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Centene
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
Ticker
$CNC
Sector
Primary listing
NYSE
Employees
60,500
Headquarters
Website
Centene Metrics
BasicAdvanced
$14B
7.09
$4.07
0.44
-
Price and volume
Market cap
$14B
Beta
0.44
52-week high
$75.78
52-week low
$25.08
Average daily volume
15M
Financial strength
Current ratio
1.098
Quick ratio
1.054
Long term debt to equity
63.818
Total debt to equity
63.909
Interest coverage (TTM)
4.94%
Profitability
EBITDA (TTM)
4,652
Gross margin (TTM)
12.68%
Net profit margin (TTM)
1.29%
Operating margin (TTM)
2.13%
Effective tax rate (TTM)
25.83%
Revenue per employee (TTM)
$2,640,000
Management effectiveness
Return on assets (TTM)
2.50%
Return on equity (TTM)
7.44%
Valuation
Price to earnings (TTM)
7.09
Price to revenue (TTM)
0.091
Price to book
0.52
Price to tangible book (TTM)
2.93
Price to free cash flow (TTM)
13.433
Free cash flow yield (TTM)
7.44%
Free cash flow per share (TTM)
2.147
Growth
Revenue change (TTM)
10.57%
Earnings per share change (TTM)
-22.58%
3-year revenue growth (CAGR)
7.28%
10-year revenue growth (CAGR)
24.01%
3-year earnings per share growth (CAGR)
8.90%
10-year earnings per share growth (CAGR)
11.31%
What the Analysts think about Centene
Analyst ratings (Buy, Hold, Sell) for Centene stock.
Bulls say / Bears say
Centene posted an unexpected adjusted Q2 2025 loss of $0.16 per share, compared to analysts' expectation of a $0.86 profit, as its medical cost ratio surged to 93%, driven by lower-than-anticipated ACA risk adjustment revenue along with higher Medicaid spending on behavioral health, home health services, and expensive specialty drugs (Reuters).
The company withdrew its 2025 GAAP and adjusted EPS guidance after preliminary ACA marketplace data from Wakely indicated market growth and morbidity levels well above its projections, resulting in a $1.8 billion expense for risk adjustment transfers (equivalent to a $2.75 per share impact), which caused Centene's shares to slump about 40% after the disclosure (Financial Times).
Political and regulatory risk remains high as the “One Big Beautiful Bill Act” introduces biennial employment verification for Medicaid members and reduces federal funding, which could lead to 7.8 million people losing Medicaid coverage and shrinking state payments. This may intensify Centene’s ongoing profitability pressures in core Medicaid regions (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Centene Financial Performance
Revenues and expenses
Centene Earnings Performance
Company profitability
Centene News
AllArticlesVideos
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Centene Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 8, 2025 – CNC
Business Wire19 hours ago
Deadline Soon: Centene Corporation (CNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Business Wire4 days ago
Centene Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CNC
Business Wire6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Centene stock?
Centene (CNC) has a market cap of $14B as of September 09, 2025.
What is the P/E ratio for Centene stock?
The price to earnings (P/E) ratio for Centene (CNC) stock is 7.09 as of September 09, 2025.
Does Centene stock pay dividends?
No, Centene (CNC) stock does not pay dividends to its shareholders as of September 09, 2025.
When is the next Centene dividend payment date?
Centene (CNC) stock does not pay dividends to its shareholders.
What is the beta indicator for Centene?
Centene (CNC) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.